Cholecystokinjn Tetrapeptide: a Provocation Agent for Research in Panic Disorder?

  • J. Bradwejn
  • D. Koszycki
  • R. Payeur
Chapter

Abstract

Panic disorder represents a significant psychiatric illness in the general population and is associated with a number of distressing and disabling complications (Marks, 1987). The core symptom of panic disorder is the repeated occurrence of panic attacks. These attacks are characterized by discrete episodes of intense anxiety or fear accompanied by somatic, cognitive and behavioural symptoms. When panic disorder is associated with extensive phobic avoidance and impairment of overall functioning a diagnosis of panic disorder with agoraphobia is made.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beinfeld, M. C. (1988). Cholecystokinin and gastrin chemistry, distribution, release, and activity. In Negro-Vilan, A. and Conn, P. M. (eds.), Peptide Hormones: Effects and Mechanisms of Action, vol. II, CRC Press, Boca Raton, Ha, 41–77.Google Scholar
  2. Bradwejn, J. and de Montigny, C. (1984). Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature, 312, 363–4.PubMedCrossRefGoogle Scholar
  3. Bradwejn, J., Koszycki, D. and Meterissian, G. (1990). Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry, 35, 83–5.PubMedGoogle Scholar
  4. Bradwejn, J., Koszycki, D., Meterissian, G. and Shriqui, C. (1989). Cholecystokinin panic: patient control differences. New Research Program and Abstracts, 142nd Meeting of American Psychiatric Association, San Francisco, NR 334, p. 183.Google Scholar
  5. Braestrup, C. and Squires, R. F. (1978). Pharmacological characterization of benzodiazepine receptors in the brain. Eur. J. Pharmacol., 48, 263–70.PubMedCrossRefGoogle Scholar
  6. Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B., Kinch, M., Aiken, B., Quadrino, L. and Heninger, G. (1986). Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. J. Clin. Psychiatry, 47, 580–6.PubMedGoogle Scholar
  7. Crowe, R. R., Noyes, R., Pauls, D. L. and Slyman, D. J. (1983). A family study of panic disorder. Arch. Gen. Psychiatry, 40, 1065–9.PubMedCrossRefGoogle Scholar
  8. de Montigny, C. (1989). Cholecystokinin-tetrapeptide induces panic-like attacks in healthy volunteers. Arch. Gen. Psychiatry, 46, 511–7.PubMedCrossRefGoogle Scholar
  9. Gorman, J. M., Liebowitz, M. R., Fyer, A. J. and Stein, J. (1989). Neuroanatomical hypothesis for panic disorder. Am. J. Psychiatry, 146, 148–61.PubMedCrossRefGoogle Scholar
  10. Gorman, J. M., Fyer, M. R., Liebowitz, M. R. and Klein, D. F. (1987). In Meltzer, H. Y. (ed.), Psychopharmacology: The Third Generation of Progress, Raven, New York, 985–93.Google Scholar
  11. Guttmacher, L. B., Murphy, D. L. and Insel, T. R. (1983). Pharmacologic models of anxiety. Compr. Psychiatry, 24, 312–26.PubMedCrossRefGoogle Scholar
  12. Karkanias, C. D., Block, G. A., Reines, S. and Bradwejn, J. (1989). Neurobiology of panic disorder. Letter, Am. J. Psychiatry, 146, 1357.Google Scholar
  13. Kubota, K., Sugaya, K., Kunagne, N. and Matsuda, I. (1985). Cholecystokinin antagonism by benzodiazepines in the contractile response of the isolated guinea pig gallbladder. Eur. J. Pharmacol., 110, 225–31.PubMedCrossRefGoogle Scholar
  14. Liebowitz, M. R., Fyer, A. J., Gorman, J. M., Campeas, R., Levin, A., Davies, S. R., Goetz, D. and Klein, D. F. (1986). Alprazolam in the treatment of panic disorder. J. Clin. Psychopharm., 6, 13–20.CrossRefGoogle Scholar
  15. Marks, I. M. (1987). Behavioural aspects of panic disorder. Am. J. Psychiatry, 144, 1160–5.PubMedCrossRefGoogle Scholar
  16. Mohler, H., Okada, T., Heiz, P. and Ulrich, J. (1978). Biochemical identification of the site of action of benzodiazepines in human brain by H3-diazepam binding. Life Sci., 22, 985–96.PubMedCrossRefGoogle Scholar
  17. Redmond, D. E. Jr (1987). Studies of the nucleus locus coeruleus in monkeys and hypothesis for neuropsychopharmacology. In Meltzer, H. Y. (ed.), Psychopharmacology: The Third Generation of Progress, Raven, New York.Google Scholar
  18. Wittchen, H. U. (1988). In Panic and Phobias 2, Hand, I. and Wittchen, H. U. (eds.), Springer, Berlin, 3–17.CrossRefGoogle Scholar
  19. Vanderhaeghen, J. J. and Crawley, J. N. (1985). Neuronal cholecystokinin. Ann. NY Acad Sci., 448, 198–219.CrossRefGoogle Scholar

Copyright information

© Macmillan Publishers Limited 1991

Authors and Affiliations

  • J. Bradwejn
    • 1
  • D. Koszycki
  • R. Payeur
  1. 1.Department of PsychopharmacologySt Mary’s Hospital CenterMontréalCanada

Personalised recommendations